Literature DB >> 33563904

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.

Abhishek Maiti1, Courtney D DiNardo1, Naval G Daver1, Caitlin R Rausch2, Farhad Ravandi1, Tapan M Kadia1, Naveen Pemmaraju1, Gautam Borthakur1, Prithviraj Bose1, Ghayas C Issa1, Nicholas J Short1, Musa Yilmaz1, Guillermo Montalban-Bravo1, Alessandra Ferrajoli1, Elias J Jabbour1, Nitin Jain1, Maro Ohanian1, Koichi Takahashi1, Philip A Thompson1, Sanam Loghavi3, Kathryn S Montalbano1, Sherry Pierce1, William G Wierda1, Hagop M Kantarjian1, Marina Y Konopleva4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33563904      PMCID： PMC7873265          DOI： 10.1038/s41408-021-00410-w

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  12 in total

1.  Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Authors:  Jorge E Cortes; Samer Khaled; Giovanni Martinelli; Alexander E Perl; Siddhartha Ganguly; Nigel Russell; Alwin Krämer; Hervé Dombret; Donna Hogge; Brian A Jonas; Anskar Yu-Hung Leung; Priyanka Mehta; Pau Montesinos; Markus Radsak; Simona Sica; Meena Arunachalam; Melissa Holmes; Ken Kobayashi; Ruth Namuyinga; Nanxiang Ge; Antoine Yver; Yufen Zhang; Mark J Levis
Journal:  Lancet Oncol       Date:  2019-06-04       Impact factor: 41.316

2.  Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa Attkisson; David C Williams; Andrea Ferreira-Gonzalez; Steven Grant
Journal:  Blood       Date:  2012-03-23       Impact factor: 22.113

Review 3.  Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

Authors:  Nicholas J Short; Marina Konopleva; Tapan M Kadia; Gautam Borthakur; Farhad Ravandi; Courtney D DiNardo; Naval Daver
Journal:  Cancer Discov       Date:  2020-02-03       Impact factor: 39.397

Review 4.  Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.

Authors:  Eunice S Wang
Journal:  Best Pract Res Clin Haematol       Date:  2019-05-12       Impact factor: 3.020

5.  Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.

Authors:  Maro Ohanian; Guillermo Garcia-Manero; Mark Levis; Elias Jabbour; Naval Daver; Gautam Borthakur; Tapan Kadia; Sherry Pierce; Jan Burger; Mary Ann Richie; Keyur Patel; Michael Andreeff; Zeev Estrov; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal:  Am J Hematol       Date:  2018-08-31       Impact factor: 10.047

6.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

7.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

8.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Authors:  Courtney D DiNardo; Abhishek Maiti; Caitlin R Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C Issa; Guillermo Montalban-Bravo; Nicholas J Short; Musa Yilmaz; Prithviraj Bose; Elias J Jabbour; Koichi Takahashi; Jan A Burger; Guillermo Garcia-Manero; Nitin Jain; Steven M Kornblau; Philip A Thompson; Zeev Estrov; Lucia Masarova; Koji Sasaki; Srdan Verstovsek; Alessandra Ferrajoli; William G Weirda; Sa A Wang; Sergej Konoplev; Zhining Chen; Sherry A Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S Welch; Hagop M Kantarjian; Marina Y Konopleva
Journal:  Lancet Haematol       Date:  2020-09-05       Impact factor: 18.959

9.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Brian A Jonas; Vinod Pullarkat; Michael J Thirman; Jacqueline S Garcia; Andrew H Wei; Marina Konopleva; Hartmut Döhner; Anthony Letai; Pierre Fenaux; Elizabeth Koller; Violaine Havelange; Brian Leber; Jordi Esteve; Jianxiang Wang; Vlatko Pejsa; Roman Hájek; Kimmo Porkka; Árpád Illés; David Lavie; Roberto M Lemoli; Kazuhito Yamamoto; Sung-Soo Yoon; Jun-Ho Jang; Su-Peng Yeh; Mehmet Turgut; Wan-Jen Hong; Ying Zhou; Jalaja Potluri; Keith W Pratz
Journal:  N Engl J Med       Date:  2020-08-13       Impact factor: 91.245

10.  Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.

Authors:  Raghuveer Singh Mali; Qi Zhang; Rosa Anna DeFilippis; Antonio Cavazos; Vinitha Mary Kuruvilla; Jayant Raman; Vidhi Mody; Edna F Choo; Monique Dail; Neil P Shah; Marina Konopleva; Deepak Sampath; Elisabeth A Lasater
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941
View more
  17 in total

Review 1.  Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.

Authors:  David C de Leeuw; Gert J Ossenkoppele; Jeroen J W M Janssen
Journal:  Curr Oncol Rep       Date:  2022-06-02       Impact factor: 5.075

Review 2.  Which FLT3 Inhibitor for Treatment of AML?

Authors:  Jayastu Senapati; Tapan Mahendra Kadia
Journal:  Curr Treat Options Oncol       Date:  2022-03-08

Review 3.  Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.

Authors:  Hagop Kantarjian; Nicholas J Short; Courtney DiNardo; Eytan M Stein; Naval Daver; Alexander E Perl; Eunice S Wang; Andrew Wei; Martin Tallman
Journal:  Lancet Haematol       Date:  2021-10-20       Impact factor: 18.959

Review 4.  Precision Medicine in Myeloid Malignancies: Hype or Hope?

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Rosalyn I Marar; Prajwal Dhakal; Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-08-16       Impact factor: 4.213

Review 5.  How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.

Authors:  Jozal W Moore; Nancy Torres; Michael Superdock; Jason H Mendler; Kah Poh Loh
Journal:  Curr Treat Options Oncol       Date:  2022-06-10

Review 6.  Resistance to targeted therapies: delving into FLT3 and IDH.

Authors:  Sai Prasad Desikan; Naval Daver; Courtney DiNardo; Tapan Kadia; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2022-06-09       Impact factor: 9.812

Review 7.  Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia.

Authors:  Giulia Ciotti; Giovanni Marconi; Giovanni Martinelli
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

8.  How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

Authors:  Abhishek Maiti; Marina Y Konopleva
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

Review 9.  New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.

Authors:  Fabio Andreozzi; Fulvio Massaro; Sebastian Wittnebel; Chloé Spilleboudt; Philippe Lewalle; Adriano Salaroli
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

Review 10.  Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.

Authors:  Jan Philipp Bewersdorf; Omar Abdel-Wahab
Journal:  Genes Dev       Date:  2022-03-01       Impact factor: 11.361
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.